Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00635375
Other study ID # 8828882
Secondary ID
Status Completed
Phase N/A
First received March 5, 2008
Last updated January 9, 2009
Start date March 2008
Est. completion date August 2008

Study information

Verified date January 2009
Source GE Healthcare
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hyperbilirubinemia is a common problem for term and preterm newborns in intensive care nurseries around the world. It is a condition in which there is too much bilirubin in the blood. Bilirubin is a substance that is naturally released when red blood cells break down. In the early newborn period, multiple factors lead to an abnormally elevated bilirubin level. Large amounts of bilirubin can circulate to tissues in the brain and may cause seizures or brain damage. About 6.1% of term newborns and a higher percentage of preterm newborns develop hyperbilirubinemia that requires treatment. Initiating treatment depends on many factors, including the cause of the hyperbilirubinemia, the level of serum indirect bilirubin, the rate of indirect bilirubin rise, and the age of the patient. The goal of treatment is to keep the level of bilirubin from rising to dangerous levels.

The bilirubin molecule absorbs light. Therefore, treatment of hyperbilirubinemia involves exposure of the baby's skin to special blue spectrum light. Phototherapy is globally recognized as the standard of care for treatment of elevated indirect hyperbilirubinemia in the neonatal period. This light exposure converts water-insoluble indirect bilirubin to a more easily excreted soluble molecule. Over the last five years, several devices have been introduced that emit high intensity light in the blue portion of the visible light spectrum. However, despite frequent use of such therapy, the effectiveness of different phototherapy devices has not been adequately compared. The objective of this study is to compare the efficacy of the blue LED fiberoptic phototherapy with the metal halide spot phototherapy versus blue LED bank light phototherapy versus a combination of tandem therapy on lowering to total serum bilirubin.


Recruitment information / eligibility

Status Completed
Enrollment 82
Est. completion date August 2008
Est. primary completion date August 2008
Accepts healthy volunteers No
Gender All
Age group N/A to 1 Month
Eligibility Inclusion Criteria:

- > 23 0/7 weeks gestation

- > 500 grams

- Non-hemolytic or presumed physiologic jaundice (within the first 14 days of life)

Exclusion Criteria:

- Known congenital infection (proven bacterial or viral etiology)

- Known hemolytic diseases such as but not limited to ABO or Rh incompatibility, minor blood group incompatibility, glucose-6-phosphate dehydrogenase deficiency, or hereditary red blood cell membrane defects (Coombs or DAT positive)

- Suspected genetic, syndromic, or hepatic disorder-

Study Design


Related Conditions & MeSH terms


Intervention

Device:
LED fiberoptic blanket phototherapy (BiliSoft blue LED fiberoptic blanket phototherapy)
35-50 mW/cm2/nm
Metal halide phototherapy (Spot PT metal halide phototherapy)
29.3-57.6 mW/cm2/nm
LED bank phototherapy (Natus neoBlue LED bank phototherapy)
12-35 mW/cm2/nm
Metal halide plus LED fiberoptic blanket phototherapy (BiliSoft and Spot PT)
29.3-57.6 mW/cm2/nm and 35-50 mW/cm2/nm

Locations

Country Name City State
United States University of Tennessee Knoxville Tennessee
United States Christiana Hospital Newark Delaware

Sponsors (1)

Lead Sponsor Collaborator
GE Healthcare

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The LED Fiberoptic Phototherapy System and metal halide spot phototherapy are will show no difference in therapeutic treatment times compared to the LED Bank Light System. 14 months
Secondary Combination Phototherapy Systems will show a 20% shorter treatment time compared to single treatment methods alone. 14 months
See also
  Status Clinical Trial Phase
Completed NCT00360204 - Improving Health Outcomes for New Mothers and Babies Phase 3
Completed NCT00383318 - Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia N/A
Completed NCT00115544 - Safety and Pharmacology of Stanate Phase 2
Completed NCT01622699 - Implementation of a Transcutaneous Bilirubinometer N/A
Terminated NCT00741117 - Conjugated Hyperbilirubinemia and Pulse Oximetry N/A
Completed NCT00288600 - Efficacy of High-dose Intravenous Immunoglobulin Therapy for Hyperbilirubinemia Due Rh Hemolytic Disease Phase 4
Completed NCT02774434 - Efficacy Study of the Draeger Jaundice Meter (JM-105) in Neonates of ≥ 24 Weeks of Gestational Age N/A
Completed NCT01550627 - Effect of Intravenous Fluid Supplementation on Serum Bilirubin and Cardiorespiratory Parameters in Preterm Infants During Phototherapy Phase 0
Completed NCT00653874 - Transcutaneous Bilirubinometry in Healthy Term and Near-Term Neonates Phase 3
Recruiting NCT03564678 - Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia Phase 2
Recruiting NCT04897113 - Study of Efficacy and Safety of the Plasmapheresis Method With Albumin Compensation Compared With the Plasmapheresis Method Without Albumin Compensation for Aging Biomarkers Correction in Men and Women Aged 40 to 55 Years Old N/A
Recruiting NCT01944696 - Cycled Phototherapy: A Safer Effective Treatment for Small Premature Infants? N/A
Completed NCT03195998 - Validity of Transcutaneous Bilirubin Monitoring in Preterm Infants
Terminated NCT02685189 - Long-Term Clinical Follow-Up of Children Enrolled in Stannsoporfin Clinical Trial Protocol No. 64,185-06-2(W)
Completed NCT02446951 - Implementation of a Clinical Decision Rule for Treatment of Neonatal Jaundice in the Emergency Department
Terminated NCT01136577 - Light-emitting Diodes (LED) Phototherapy for Hyperbilirubinemia of Term Newborn N/A
Completed NCT04271098 - The Investigation of the Causes of Hepatic Dysfunction in the Postoperative Period During Open-heart Surgeries
Completed NCT02691156 - Bilirubin Binding Capacity to Assess Bilirubin Load in Preterm Infants
Completed NCT00004381 - Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia Phase 2
Completed NCT00004382 - Phase II Study of Tin Mesoporphyrin vs Phototherapy for Hyperbilirubinemia in Premature Newborns Phase 2